drugset / Trial / NCT05427396
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.
Timeline
- Start
- 2022-07-28
- Primary completion
- 2024-01-15
- Completion
- 2024-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tifcemalimab | Monoclonal antibody | 200 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |